Abstract
Recently, molecule-based targeted therapy has achieved remarkable success in clinical, and opened up a new era particulraly in the field of cancer therapy. Monoclonal antibodies and small molecule inhibitors are two pillars of this field. Additionally, a single-strand nucleic acid molecule called “chemical antibody” has also attracted increasing attention. These novel targeting agents are called “nucleic acid aptamers (aptamers)”. With high specificity and affinity for a variety of target molecules, nucleic acid aptamers represent a new direction in the gene targeting therapy. In this review, we summarizes the recent development of aptamers and their druggability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
